With AI, the tools are ready and the budgets are allocated, but they are flowing to the wrong places, write Romi Singh, Ph.D. and Jared R. Auclair, Ph.D.
Early oncology trial decisions can lock in risk, shape regulatory confidence, and limit flexibility. Knowing which choices are hardest to reverse protects optionality and credibility.
As consumers increasingly expect convenience and immediacy, the on-demand model continues to reshape how services are delivered across nearly every sector.
Charlotte’s health innovation community is gaining momentum through new networks, shared spaces, and startup support programs, turning collaboration into a catalyst for growth across the region.
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
Designed for leaders and professionals in the life sciences sector, this piece provides a practical framework for transforming data management into a catalyst for efficiency, compliance, and long-term innovation.
As global pricing reforms evolve and policies gain traction, stakeholders must critically reassess the role of International Reference Pricing in balancing affordability, access, and incentives for innovation.
Unlock more accurate clinical trial matching by using AI to interpret complex patient notes, reducing the manual screening burden and identifying eligible candidates with higher precision.
When partnering with CDMOs, success depends heavily on collaboration with a partner that combines deep technical expertise with a proven record of regulatory excellence and operational reliability.
